Loading…
Live market data via Yahoo Finance · updated 7/12/2026
KalVista Pharmaceuticals, Inc. is a healthcare company that develops oral therapies for rare diseases in worldwide markets. It offers sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE), and an oral Factor XIIa inhibitor program.
The company was formerly KalVista Pharmaceuticals Ltd. and changed its name to KalVista Pharmaceuticals, Inc. in November 2016. It is headquartered in Framingham, Massachusetts. As of June 11, 2026, KalVista Pharmaceuticals, Inc. was taken private and operates as a subsidiary of Chiesi Farmaceutici S.p.A.
KalVista Pharmaceuticals Inc (KALV) sits in the Healthcare sector. Its current price is $27.00 and its market capitalization is $1.44B. It ranks 2290.
As of June 11, 2026, KalVista Pharmaceuticals, Inc. was taken private and operates as a subsidiary of Chiesi Farmaceutici S.p.A.
A major floor 46.7% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 0.9% above — clearing it would confirm fresh momentum.
Key KALV support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KALV market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $27.00 | Buy | $26.99 | Buy |
| MA 10 | $26.97 | Buy | $26.95 | Buy |
| MA 20 | $26.88 | Buy | $26.60 | Buy |
| MA 50 | $24.29 | Buy | $24.46 | Buy |
| MA 100 | $20.30 | Buy | $21.61 | Buy |
| MA 200 | $16.98 | Buy | $18.55 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 75.89 | Sell |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 87.68 | Neutral |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | -0.21 | Sell |
| ROC (12) | 0.78 | Buy |
| Bollinger %B (20,2) | 0.81 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.52 | Buy |
| Awesome (5,34) | 0.63 | Buy |
| Ultimate (7,14,28) | 92.49 | Sell |
| Momentum (10) | 0.13 | Buy |
| Aroon Osc (25) | 92.00 | Buy |
| Hull MA (9) | 27.01 | Sell |
| ADX (14) | 47.24 | Buy |
| ATR (14) | 0.12 | Info |
The 30-day technical picture is bullish with RSI14 at 80. The 50-day simple moving average (SMA50) is $24.29 and the 200-day simple moving average (SMA200) is $16.98, indicating an uptrend. Support is at $26.65 and resistance at $27.00. The thirty-day range spans from $24.44 to $29.83, and annualized volatility is 30%.
With a current price of $27.00, the price sits near the stated resistance of $27.00 and above the $26.65 support level; the range suggests potential upside if momentum continues, though RSI at 80 points to overbought conditions in the near term.
See what a past investment in KALVwould be worth at today's price.
$1,000 invested in KALV on Jun 12, 2025 (≈ 76.394193 KALV) would be worth
$2,062.64
+$1,062.64 (+106.3%) today · 2.06× · US Dollar
Based on a KALV entry price of $13.09 vs. today's $27.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $26.95 | $1,001.86 | +0.2% |
| 1 month ago | $26.8 | $1,007.46 | +0.7% |
| 3 months ago | $16.94 | $1,593.86 | +59.4% |
| 6 months ago | $16.9 | $1,597.63 | +59.8% |
| 1 year ago | $13.09 | $2,062.64 | +106.3% |
| All time (4.9y) ago | $21.81 | $1,237.96 | +23.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
The multi-year forecast shows a bullish trajectory from 2027 onward, with rising average prices and ROIs:
- 2026: min $14.40, avg $27.00, max $36.69, ROI 0, sentiment Neutral. - 2027: min $27.96, avg $34.18, max $43.70, ROI 26.6, sentiment Bullish. - 2028: min $32.40, avg $40.34, max $52.96, ROI 49.4, sentiment Bullish.
- 2029: min $41.41, avg $52.34, max $70.16, ROI 93.8, sentiment Bullish. - 2030: min $48.40, avg $62.00, max $84.59, ROI 129.6, sentiment Bullish. - 2031: min $55.38, avg $71.80, max $99.50, ROI 165.9, sentiment Bullish.
- 2032: min $59.67, avg $78.24, max $109.95, ROI 189.8, sentiment Bullish. - 2033: min $61.32, avg $81.25, max $115.65, ROI 200.9, sentiment Bullish. - 2034: min $71.49, avg $95.67, max $137.80, ROI 254.3, sentiment Bullish.
- 2035: min $79.77, avg $107.75, max $156.93, ROI 299.1, sentiment Bullish. - 2040: min $125.38, avg $176.62, max $269.54, ROI 554.2, sentiment Bullish. - 2050: min $275.17, avg $415.71, max $679.93, ROI 1439.7, sentiment Bullish.
Overall, the long-term outlook is bullish across the forecasted years, with higher average prices and expanding ROIs. These figures are estimates and not guarantees, reflecting potential upside under the stated assumptions and market conditions.
Tap a question to reveal the answer.
In 2030, the forecast shows min $48.40, avg $62.00, max $84.59; ROI 129.6; sentiment Bullish.
The forecast shows bullish sentiment from 2027 onward, with rising averages (e.g., $34.18 in 2027, $62.00 in 2030) and ROIs up to 129.6% by 2030 and 1439.7% by 2050. The year 2026 is Neutral with an avg of $27.00.
Yes. The 2031 max is $99.50, and the 2032 max is $109.95, indicating the price could reach and exceed $100 by 2032.
The current price is $27.00 and the market cap is $1.44B. It ranks 2290.
RSI14 is 80, indicating bullish momentum. The 30-day range is $24.44 to $29.83, with support at $26.65 and resistance at $27.00. The SMA50 is $24.29 and the SMA200 is $16.98, and annualized volatility is 30%.
KalVista Pharmaceuticals Inc Community Discussion
0Share your KalVista Pharmaceuticals Inc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.